EBSEmergent BioSolutions Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$126K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now 51% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can EBS take a bad year?
The deepest fall in EBS's price history on file is −99%; it is 51% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 85%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −99%
Worst drawdown on file · −51% today
Details›
- Total debtQ2 2026
- $582M
- Cash and short-term investments
- $140M
- Net debt
- $442M
- EBITDA, trailing twelve months
- −$5.1M
- Operating profit, trailing twelve months
- −$66M
- Debt / equity
- 1.70×
- Annualised volatilitytwo years of daily moves
- 85%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 51%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore